Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

1.

Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.

Barrios V, Escobar C.

Expert Rev Cardiovasc Ther. 2013 Feb;11(2):129-41. doi: 10.1586/erc.12.172. Review.

PMID:
23405833
[PubMed - indexed for MEDLINE]
2.

Rivaroxaban in atrial fibrillation.

Giorgi MA, Miguel LS.

Vasc Health Risk Manag. 2012;8:525-31. doi: 10.2147/VHRM.S19825. Epub 2012 Aug 30.

PMID:
22973107
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
[PubMed - indexed for MEDLINE]
4.

Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.

Paikin JS, Manolakos JJ, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2012 Aug;10(8):965-72. doi: 10.1586/erc.12.91. Review.

PMID:
23030284
[PubMed - indexed for MEDLINE]
5.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
[PubMed - indexed for MEDLINE]
6.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
[PubMed - indexed for MEDLINE]
7.

Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators.

Circ J. 2013;77(3):632-8. Epub 2012 Dec 8.

PMID:
23229461
[PubMed - indexed for MEDLINE]
Free Article
8.

Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Carter NJ, Plosker GL.

Drugs. 2013 May;73(7):715-39. doi: 10.1007/s40265-013-0056-9. Review.

PMID:
23677801
[PubMed - indexed for MEDLINE]
9.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

PMID:
23391196
[PubMed - indexed for MEDLINE]
Free Article
10.

A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.

Kasmeridis C, Lip GY, Apostolakis S.

Hosp Pract (1995). 2013 Feb;41(1):61-70. doi: 10.3810/hp.2013.02.1011. Review.

PMID:
23466968
[PubMed - indexed for MEDLINE]
11.

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators.

Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

PMID:
23212720
[PubMed - indexed for MEDLINE]
Free Article
12.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

PMID:
22787066
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

ROCKET AF Study Investigators.

Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025.

PMID:
20211293
[PubMed - indexed for MEDLINE]
14.

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).

Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC; ROCKET AF Investigators.

Circulation. 2014 May 6;129(18):1850-9. doi: 10.1161/CIRCULATIONAHA.113.005754. Epub 2014 Feb 19.

PMID:
24552831
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF.

Tanahashi N, Hori M, Matsumoto M, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF Study Investigators.

J Stroke Cerebrovasc Dis. 2013 Nov;22(8):1317-25. doi: 10.1016/j.jstrokecerebrovasdis.2012.12.010. Epub 2013 Jan 22.

PMID:
23352688
[PubMed - indexed for MEDLINE]
17.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
[PubMed - indexed for MEDLINE]
18.

Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.

Morell J, Sullivan B, Khalabuda M, McBride BF.

J Clin Pharmacol. 2010 Sep;50(9):986-1000. doi: 10.1177/0091270009355814. Epub 2010 Feb 2.

PMID:
20124518
[PubMed - indexed for MEDLINE]
19.

Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.

Lenchus JD.

Hosp Pract (1995). 2013 Feb;41(1):49-60. doi: 10.3810/hp.2013.02.1007.

PMID:
23466967
[PubMed - indexed for MEDLINE]
20.

Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.

Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1.

PMID:
24189454
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk